160.
Discrimination between alphaz-adrenoceptors and [3H]idazoxan-labelled
nonadrenergic sites in rabbit white fat cells / D. Langin [et al.] // Eur. J.
Pharmacol. – 1990. – Vol. 188, № 4-5. – P. 261-272.
161.
Commentary to the article: ONTARGET Investigators, Yusuf S,
Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for
vascular events. N Engl J Med 2008; 358: 1547-59 / M.
//
– 2008. – Vol. 66, № 6. – P. 705-706.
162.
Dubey L. Role of leptin in atherogenesis / L. Dubey, Z. Hesong // Exp. Clin.
Cardiol. – 2006. – Vol. 11, № 4. – P. 269-275.
163.
Effect of antihypertensive treatment on small arteries of patients with
previously untreated essential hypertension / N. K. Thybo [et al.] // Hypertension.
– 1995. – Vol. 25, № 4. – P. 474-481.
164.
Effect of indapamide SR in the treatment of hypertensive patients with type 2
diabetes / S. W. Kuo [et al.] // Am. J. Hypertens. – 2003. – Vol. 16, №. 8. – P.
623-628.
165.
Effect of Low-dose perindopril/indapamide on albuminuria in diabetes:
preterax in albuminuria regression: PREMIER / C. E. Mogensen [et al.] //
Hypertension. – 2003. – Vol. 41. – P. 1063-1071.
166.
Effects of a fixed combination of perindopril and indapamide on
macrovascular and microvascular outcomes in patients with type 2 diabetes
mellitus (the ADVANCE trial): a randomised controlled trial / A. Patel [et al.] //
Lancet. – 2007. – Vol. 370, № 9590. – P. 829-940.
167.
Effects of agmatine and moxonidine on glucose metabolism: An integrated
approach towards pathophysiological mechanisms in cardiovascular metabolic
disorders / E. C. Kaan [et al.] // Cardiovasc. Risk Factors. – 1996. – Vol. 5. – P.
19-27.
168.
Effects of moxonidine on the sympathetic nervous system, blood pressure,
plasma renin activity, plasma aldosterone, leptin, and metabolic profile in obese
